Waltermire Robert E.
- SEC CIK
- 0001876996
No open-market purchases or sales filed in the past year.
Current role at each company
- MDGL Madrigal Pharmaceuticals, Inc.Senior VP, Chief Pharma Dev.as of Mar 7, 2025
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Waltermire Robert E. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2023 (view filing) | Feb 28-Mar 1 | 2 days | Waltermire Robert E.Senior VP, Chief Pharma Dev. | SSale | −10.0K | $273.24 | −$2.73M | −63.8%5.67K after | 6 lots |
| Dec 14, 2023 (view filing) | Dec 12-13 | 2 days | Waltermire Robert E.Senior VP, Chief Pharma Dev. | SSale | −3.80K | $222.82 | −$846.7K | −40.1%5.67K after | 4 lots |
| Dec 18, 2023 (view filing) | Dec 14-15 | 4 days | Waltermire Robert E.Senior VP, Chief Pharma Dev. | SSale | −4.00K | $235.50 | −$942.0K | −41.4%5.67K after | 4 lots |
| May 23, 2024 (view filing) | May 21 | 2 days | Waltermire Robert E.Senior VP, Chief Pharma Dev. | SSale | −1.04K | $231.34 | −$239.7K | −15.9%5.50K after | |
| Jun 14, 2024 (view filing) | Jun 12 | 2 days | Waltermire Robert E.Senior VP, Chief Pharma Dev. | SSale | −2.00K | $285.00 | −$570.0K | −26.7%5.50K after | |
| Jun 18, 2024 (view filing) | Jun 14 | 4 days | Waltermire Robert E.Senior VP, Chief Pharma Dev. | SSale | −1.90K | $280.00 | −$532.0K | −25.7%5.50K after | |
| Jan 17, 2025 (view filing) | Jan 17 | Same day | Waltermire Robert E.Senior VP, Chief Pharma Dev. | SSale | −442 | $273.41 | −$120.8K | −8.0%5.06K after | |
| Jan 27, 2025 (view filing) | Jan 24 | 3 days | Waltermire Robert E.Senior VP, Chief Pharma Dev. | SSale | −103 | $335.24 | −$34.5K | −2.0%4.96K after | |
| Mar 4, 2025 (view filing) | Feb 28 | 4 days | Waltermire Robert E.Senior VP, Chief Pharma Dev. | SSale | −1.23K | $341.07 | −$418.5K | −24.8%3.73K after | 2 lots |
| Mar 7, 2025 (view filing) | Mar 5 | 2 days | Waltermire Robert E.Senior VP, Chief Pharma Dev. | SSale | −14.1K | $341.33 | −$4.82M | −79.1%3.73K after | 9 lots |